Lipella Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 7
- Market Cap
- $3.7M
- Website
- http://www.lipella.com
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Evaluating LP-10 in Subjects With OLP
- Conditions
- Oral Lichen Planus
- Interventions
- Drug: LP-10 (Liposomal Tacrolimus)
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Lipella Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06233591
- Locations
- 🇺🇸
Center for Dermatology, Fremont, California, United States
🇺🇸UCSF School of Dentistry, San Francisco, California, United States
🇺🇸Miami Cancer Institue at Baptist Health, Inc, Miami, Florida, United States
The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Lipella Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT03129126
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome
- Conditions
- Interstitial Cystitis
- Interventions
- Drug: LP-08 20mgDrug: LP-08 80mgDrug: Normal saline
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Lipella Pharmaceuticals, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT01393223
- Locations
- 🇺🇸
William Beaumont Hospitals, Royal Oak, Michigan, United States
News
Lipella Pharmaceuticals Secures Patent for MRI-Based Diagnostic Technology to Detect Interstitial Cystitis
Lipella Pharmaceuticals received U.S. Patent No. 12,326,492 for an MRI-based method to detect lesions in body cavities, specifically targeting interstitial cystitis diagnosis.
Lipella Pharmaceuticals Renews Manufacturing Partnership with Cook MyoSite to Advance Oral Lichen Planus Treatment
Lipella Pharmaceuticals has re-signed its manufacturing collaboration agreement with Cook MyoSite to support Chemistry, Manufacturing and Control documentation for clinical products LP-10 and LP-310.
Lipella Completes Enrollment in Phase IIa Trial for Novel Oral Lichen Planus Treatment
Lipella Pharmaceuticals has completed enrollment in its Phase IIa trial evaluating LP-310, a liposomal tacrolimus oral rinse, for treating oral lichen planus across three dose cohorts at seven US trial sites.
FDA Grants Expanded Access Program for Lipella's LP-310 in Oral Lichen Planus Treatment
The FDA has approved an Expanded Access Program for LP-310, an innovative oral rinse therapy targeting oral lichen planus, a condition affecting 6 million Americans with no current FDA-approved treatments.
Lichen Planus Pipeline Shows Promise with Emerging Therapies
A new report highlights the unmet need for targeted Lichen Planus (LP) treatments, as current options primarily offer palliative care.
Lipella's LP-310 Shows Positive Phase 2a Results for Oral Lichen Planus
Lipella Pharmaceuticals' LP-310, a liposomal-tacrolimus oral rinse, demonstrated statistically significant improvements in treating oral lichen planus (OLP).
Lipella Pharmaceuticals' LP-310 Shows Promise in Phase 2a Trial for Oral Lichen Planus
Lipella Pharmaceuticals completes the first cohort dosing in its Phase 2a trial of LP-310 for Oral Lichen Planus (OLP).
Lipella Pharmaceuticals' Liposomal Delivery Platform Secures U.S. Patent, Extending Market Exclusivity
Lipella Pharmaceuticals received U.S. Patent No. 12,138,345 for its liposomal drug delivery platform, enhancing targeted therapeutic agent delivery.